Compounds > 6-hydroxy-2,4,5-triaminopyrimidine
Page last updated: 2024-10-15

6-hydroxy-2,4,5-triaminopyrimidine

Description

6-hydroxy-2,4,5-triaminopyrimidine: pyrimidine moiety of pterins; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,5,6-triamino-4-hydroxypyrimidine : A member of the class of aminopyrimidines that is 2,5,6-triaminopyrimidine carrying an additional hydroxy substituent at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135406869
CHEMBL ID2151965
CHEBI ID137796
SCHEMBL ID33967
SCHEMBL ID12283982
MeSH IDM0041628

Synonyms (72)

Synonym
2,5,6-triamino-4-pyrimidinol
4(1h)-pyrimidinone, 2,5,6-triamino-
2,4,5-triamino-6-oxypyrimidine
2,4,5-triamino-6-pyrimidinol
2,5,6-triamino-4(1h)-pyrimidinone
2,5,6-triamino-4-oxopyrimidine
2,4,5-triaminopyrimidin-6(1h)-one
6-hydroxy-2,4,5-triaminopyrimidine
nsc 9313
einecs 213-725-4
CHEMDIV1_000151 ,
2,5-triaminopyrimidin-6(1h)-one
6-hydroxy-2,5-triaminopyrimidine
2,5-triamino-6-pyrimidinol
2,5-triamino-6-hydroxypyrimidine
2,6-triamino-4-pyrimidinone
nsc9313
4(1h)-pyrimidinone,5,6-triamino-
1004-75-7
nsc-9313
2,6-triamino-4-oxopyrimidine
2,6-triamino-4-pyrimidinol
2,5,6-triamino-4-pyrimidol
2,5,6-triaminopyrimidin-4-ol
6-hydroxy-2,4,5-triaminopyrimidine sulfate (salt)
H-7780
CHEBI:137796
2,5,6-triaminopyrimidin-4(1h)-one
4-hydroxy-2,5,6-triaminopyrimidine
2,5,6-triamino-4-hydroxypyrimidine
AC-519
2,5,6-triamino-1h-pyrimidin-4-one
HMS587G19
AKOS005266596
NCGC00188279-01
NCGC00188279-02
0fu ,
2,4,5-triamino-6-hydroxypyrimidine
AKOS006223700
BCP9000003
2,5,6-triaminopyrimidin-4(3h)-one
4(3h)-pyrimidinone, 2,5,6-triamino-
fr001fjw89 ,
unii-fr001fjw89
CHEMBL2151965
FT-0649647
2,5,6-triamino-4-pyrimidinone
folic acid hydrate impurity b [ep impurity]
4-pyrimidinol, 2,5,6-triamino-
SCHEMBL33967
2,4,5-triamino-6-hydroxy-pyrimidine
2,5,6-triamino-4-hydroxyprimidine
DTXSID3061396
SCHEMBL12283982
CS-W019346
W-108959
2,4,5-triamino-6-hydroxypyrimidine sulfate salt
mfcd00464828
GS-6349
2,5,6-triamino-3,4-dihydropyrimidin-4-one
6-hydroxy-2,4,5-triaminopyrimidine sulfate salt, 97%
2,4,5-triamino-6-hydroxy pyrmidine
BCP22760
F15011
2,5,6-triamino-4-oxo-3,4-dihydropyrimidine
AMY085
H10458
Q27278143
2,4,5-triamino-1h-pyrimidin-6-one
2,4,5-triamino-6-hydroxpyrimidine
EN300-83038
triaminopyrimidin-4-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
chromophoreThe part (atom or group of atoms) of a molecular entity in which the electronic transition responsible for a given spectral band is approximately localized.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
hydroxypyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency12.58930.000811.382244.6684AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID691400Drug degradation in DMSO assessed as 2,6,8-triaminopyrimido[5,4-g]pteridin-4(3H)-one formation at 10 mM incubated over 2 months by UV-Vis spectrophotometry2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691395Drug degradation in DMSO2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691397Drug degradation in DMSO assessed as oxidation after overnight incubation2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID1348886Binding affinity to Staphylococcus aureus [5'-32P]guaA riboswitch by polyacrylamide gel electrophoresis method2018European journal of medicinal chemistry, Jan-01, Volume: 143Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridioides difficile.
AID691405Drug degradation in DMSO assessed as 2,6-diamino-5-(2,6-diamino-4-oxopyrimidin-5(4H)-ylideneamino)pyrimidin-4(3H)-one formation after 11 days by UV-Vis spectrophotometry2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691403Drug degradation in DMSO assessed as ammonium cation formation after 2 days by NMR spectroscopy2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691401Drug degradation in DMSO after 7 days by NMR spectroscopy2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691406Drug degradation in DMSO assessed as 2,6,8-triaminopyrimido[5,4-g]pteridin-4(3H)-one formation after 11 days by UV-Vis spectrophotometry2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID1204897Antibacterial activity against Staphylococcus aureus in rich cation-adjusted Muller-Hinton broth in presence of 1.5 mM DTT2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
(Dis)similar Analogues of Riboswitch Metabolites as Antibacterial Lead Compounds.
AID691402Drug degradation in DMSO assessed as 2,6-diamino-5-(2,6-diamino-4-oxopyrimidin-5(4H)-ylideneamino)pyrimidin-4(3H)-one formation after 1 day by NMR spectroscopy2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID1204896Antibacterial activity against Staphylococcus aureus in rich cation-adjusted Muller-Hinton broth2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
(Dis)similar Analogues of Riboswitch Metabolites as Antibacterial Lead Compounds.
AID691408Drug degradation in alkalised DMSO assessed as 2,6,8-triaminopyrimido[5,4-g]pteridin-4(3H)-one formation after 24 hrs2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691399Drug degradation in DMSO assessed as 2,6-diamino-5-(2,6-diamino-4-oxopyrimidin-5(4H)-ylideneamino)pyrimidin-4(3H)-one formation at 10 mM incubated over 2 months by UV-Vis spectrophotometry2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691409Drug degradation in acidified DMSO2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691398Drug degradation in DMSO assessed as oxidation after two months2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID691404Drug degradation in DMSO assessed as 2,6,8-triaminopyrimido[5,4-g]pteridin-4(3H)-one after 87 days by NMR spectroscopy2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID1204895Binding affinity to guanine riboswitch in Bacillus subtilis2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
(Dis)similar Analogues of Riboswitch Metabolites as Antibacterial Lead Compounds.
AID691407Drug degradation in alkalised DMSO assessed as 2,6-diamino-5-(2,6-diamino-4-oxopyrimidin-5(4H)-ylideneamino)pyrimidin-4(3H)-one formation2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's1 (10.00)18.2507
2000's0 (0.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diacetyl
butane-2,3-dione : An alpha-diketone that is butane substituted by oxo groups at positions 2 and 3. It is a metabolite produced during the malolactic fermentation.		1.9910alpha-diketoneEscherichia coli metabolite;
Saccharomyces cerevisiae metabolite
pyruvaldehyde
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.. methylglyoxal : A 2-oxo aldehyde derived from propanal.		1.99102-oxo aldehyde;
propanals		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2,2'-dipyridyl
2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.		1.9510bipyridinechelator;
ferroptosis inhibitor
mercaptoethanol
Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.		1.9510alkanethiol;
primary alcohol		geroprotector
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		3.2110aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		1.9510antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
glyoxal
[no description available]		1.9910dialdehydeagrochemical;
allergen;
pesticide;
plant growth regulator
homoarginine
L-homoarginine : An L-lysine derivative that is the L-enantiomer of homoarginine.		3.2110homoarginine;
L-lysine derivative;
non-proteinogenic L-alpha-amino acid		biomarker;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
human metabolite;
rat metabolite;
xenobiotic metabolite
indophenol
Indophenol: A deep blue dye (with the formula OC6H4NC6H4OH) used to detect AMMONIA in a common test called the Berthelot's reaction and to detect PARACETAMOL by spectrophotometry.. indophenol : A quinone imine obtained by formal condensation of one of the keto groups of benzoquinone with the amino group of 4-hydroxyaniline.		1.9610quinone iminedye
5-aminouracil
[no description available]		2.0710
2,6-dichloroindophenol
2,6-Dichloroindophenol: A dye used as a reagent in the determination of vitamin C.. 2,6-dichloroindophenol : A quinone imine that is indophenol substituted by chloro groups at positions 2 and 6.. N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine : 1,4-benzoquinone imine having a 3,5-dichloro-4-hydroxyphenyl substituent attached to the nitrogen atom.		1.9610dichlorobenzene;
quinone imine
5,6-diamino-2,4-dihydroxypyrimidine
5,6-diamino-2,4-dihydroxypyrimidine: structure given in first source; RN given refers to parent compound. 5,6-diaminouracil : An aminouracil in which the ring hydrogens at positions 5 and 6 on uracil have been replaced by amino groups.		2.0710aminouracil;
diamine;
pyrimidone
s-2-aminoethyl cysteine
S-2-aminoethyl cysteine: inhibits protein synthesis in mammalian cells; RN given refers to parent cpd; structure. L-thialysine : A cysteine derivative that is the S-(2-aminoethyl) analogue of L-cysteine; reported to have cytotoxic effects.		3.2110L-cysteine thioether;
non-proteinogenic L-alpha-amino acid		EC 5.4.3.2 (lysine 2,3-aminomutase) inhibitor;
metabolite;
protein synthesis inhibitor
2-amino-n(6)-hydroxyadenine
2-amino-N(6)-hydroxyadenine: mutagen & bacterial growth inhibitor; structure in first source. 2-amino-6-hydroxyaminopurine : A 2,6-diaminopurine that is the N(6)-hydroxy derivative of 2,6-diamino-3H-purine.		3.21102,6-diaminopurines;
hydroxylamines;
nucleobase analogue		mutagen;
teratogenic agent
i-677
4-oxalysine: from Streptomyces reseoviridofuscus; RN given refers to cpd without isomeric designation. O-(2-aminoethyl)-L-serine : An L-alpha-amino acid that is L-serine in which the hydroxy group at position 3 is converted to the corresponding 2-aminoethyl ether. An antimetabolic antibiotic obtained from Streptomyces reseoviridofuscus.		3.2110L-serine derivative;
non-proteinogenic L-alpha-amino acid		antimetabolite;
antimicrobial agent;
antineoplastic agent;
metabolite
riboflavin
vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).		7.3620flavin;
vitamin B2		anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite
dehydrolysine
[no description available]		3.2110
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		2.3620organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
guanine
[no description available]		3.64202-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
9-methylguanine
9-methylguanine: structure in first source		2.1710
2,4-diaminohypoxanthine
2,4-diaminohypoxanthine: do not confuse abbreviation DAHP with various dehydro-deoxy-arabino-heptulosonic acid phosphates which also use DAHP; RN given refers to parent cpd; structure		2.0710hydroxypyrimidine
divicine
divicine: RN given refers to parent cpd		2.3620
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		2.3620
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		03.0310
Bacterial Infections
Infections by bacteria, general or unspecified.		03.0310
Deficiency, Riboflavin
[description not available]		01.9510